Therapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, and make up a major proportion of blockbuster drugs with global sales of more than US$230bn in 2023.
European biotechs navigating a new financing environment
OpinionAfter the exuberance during the Covid-boost and the post-Covid hangover, 2024 was a rather calm year for the biotechnology sector. This provides an opportunity to take a step back and assess some emerging long-term financing trends as well as the recent events in the US, which may also impact the biotech industry.
New Chief Commercial Officer on board
AppointmentsCambridge-based 4basebio PLC announced the appointment of Gabe Longoria as Chief Commercial Officer.
Augustine Therapeutics NV raises €78m in Series A round
Latest NewsLeuven-based Augustine Therapeutics NV will use the proceeds from a €77.7m in Series A financing led by Novo Holdings and Jeito Capital to advance its preclinical HDAC6 inhibitor AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease to Phase I testing.
Trump’s win will affect the biotechnology sector
OpinionDuring the conference calls on the latest quarterly reports, several recurring questions emerged: What consequences do you anticipate if Trump is to be re-elected? How will tariffs affect supply chains and operating profits? What about FDA, IRA, the healthcare system, or the bioeconomy strategy?
The golden age of engineered therapeutic antibodies
OpinionTherapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, and make up a major proportion of blockbuster drugs with global sales of more than US$230bn in 2023.
UK to boost scale-up of biomanufacturing infrastructure
Latest NewsThe House of Lords Science and Technology Committee wants to improve technology transfer in industrial biotechnology through better regulation, more funding, and improved access to scale-up infrastructure for biomanufacturing and bioengineering start-ups.
The tenth pin for quality management in life sciences
BackgroundThe much-discussed digital transformation in the healthcare sector is in full swing. European Biotechnology spoke with Dr. Sabrina Graf, COO of the globally active Tenthpin Group, about how the right software can improve quality management, keep the system landscape lean, and safe both, time and money.
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager DR-201
Latest NewsFrench Sanofi SA announced that it will acquire Dren Bio Inc’s bispecific myeloid cell engager DR-0201 for upfront US$600m and US$1.3bn in milestones. The deal is expected to close in Q2/2025.
Brainomix Ltd. completes £14m Series C financing
Latest NewsUniversity of Oxford spinout Brainomix Ltd has closed a £14m Series C round to advance its commercial expansion in the US. Funding will also support clinical uptake of its AI imaging technology in stroke and lung fibrosis.
US President deprioritises biotechnology
Latest NewsThe U.S. administration of President Donald Trump has revoked Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” originally issued on September 12, 2022. This decision will have far-reaching consequences for the U.S. biotech industry.